The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. With multiple clinical programs ongoing including two Phase 3 trials, the company is transitioning from clinical-stage toward a commercial enterprise.
Cyborg Score Rationale
Early-stage biotech with two Phase 3 trials and promising candidates, but extremely low stock valuation (~$1.18), underperformance vs. industry, and significant shareholder dilution indicate execution risk and market skepticism.
Top Insights
Lead drug candidate Trappsol Cyclo is in Phase 3 clinical trial for Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder.
Recent merger with Cyclo Therapeutics brings together companies with mission to deliver breakthrough treatment for Niemann Pick Type C1.
Operates in three segments: Healthcare, Infusion Technology, and Real Estate.
Developing Promitil for targeted delivery of mitomycin-C, having completed Phase 1A and 1B clinical studies for advanced cancer patients.
Named Competitors
CPI-613 (devimistat) — Phase II cancer therapeutic targeting metabolic pathways